Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
Sarepta Therapeutics, Inc. (SRPT)
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investorrelations.sarepta.com/events-and-presentations
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2019. “As we pass through mid-2019, we are very pleased to announce strong performance and solid execution against our goals. EXONDYS 51®(eteplirsen) continues to perform, with second quarter sales at $94.7 million, 29% growth quarter over same quarter last year. In our RNA franchise, we advanced our VYONDYS 53™(golodirsen) application, with an FDA PDUFA date of August 19, are preparing to submit for casimersen, with a target PDUFA date in the first half of 2020, and have commenced dosing our PPMO SRP-5051 MAD trial. With respect to our gene therapy platform, we have completed the dosing of the 24 patients in our placebo-controlled micro-dystrophin trial as forecasted, made significant progress in the build out of our commercial micro-dystrophin process and manufacturing
Show less
Read more
Impact Snapshot
Event Time:
SRPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SRPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SRPT alerts
High impacting Sarepta Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SRPT
News
- Has Sarepta Therapeutics (SRPT) Fallen Too Far After 82% One-Year Share Price Drop? [Yahoo! Finance]Yahoo! Finance
- Sarepta Preliminary Results: Not What The Market Wanted To Hear [Seeking Alpha]Seeking Alpha
- Sarepta Therapeutics: Is Elevidys A Bust? [Seeking Alpha]Seeking Alpha
- Sarepta Therapeutics (NASDAQ:SRPT) had its price target raised by analysts at Royal Bank Of Canada from $16.00 to $18.00. They now have a "sector perform" rating on the stock.MarketBeat
- Sarepta Therapeutics (NASDAQ:SRPT) had its "sell" rating reaffirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
SRPT
Earnings
- 11/3/25 - Beat
SRPT
Sec Filings
- 1/12/26 - Form 8-K
- 12/19/25 - Form 4
- 12/19/25 - Form 8-K
- SRPT's page on the SEC website